KR102129247B1 - 오피오이드 수용체 리간드와 그 용도 및 제조방법 - Google Patents

오피오이드 수용체 리간드와 그 용도 및 제조방법 Download PDF

Info

Publication number
KR102129247B1
KR102129247B1 KR1020197016977A KR20197016977A KR102129247B1 KR 102129247 B1 KR102129247 B1 KR 102129247B1 KR 1020197016977 A KR1020197016977 A KR 1020197016977A KR 20197016977 A KR20197016977 A KR 20197016977A KR 102129247 B1 KR102129247 B1 KR 102129247B1
Authority
KR
South Korea
Prior art keywords
acid
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016977A
Other languages
English (en)
Korean (ko)
Other versions
KR20190072665A (ko
Inventor
데니스 야마시타
디미터 고트체브
필립 피티스
샤오-타오 첸
곽동 뤼
캐서린 씨.케이. 위안
Original Assignee
트레베나, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46877853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102129247(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 트레베나, 인코포레이티드. filed Critical 트레베나, 인코포레이티드.
Publication of KR20190072665A publication Critical patent/KR20190072665A/ko
Application granted granted Critical
Publication of KR102129247B1 publication Critical patent/KR102129247B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197016977A 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법 Active KR102129247B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161466809P 2011-03-23 2011-03-23
US61/466,809 2011-03-23
US201261596808P 2012-02-09 2012-02-09
US61/596,808 2012-02-09
PCT/US2012/030327 WO2012129495A1 (en) 2011-03-23 2012-03-23 Opioid receptor ligands and methods of using and making same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137027288A Division KR101991327B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법

Publications (2)

Publication Number Publication Date
KR20190072665A KR20190072665A (ko) 2019-06-25
KR102129247B1 true KR102129247B1 (ko) 2020-07-06

Family

ID=46877853

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197016977A Active KR102129247B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법
KR1020137027288A Active KR101991327B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법
KR1020187025108A Active KR101991326B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137027288A Active KR101991327B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법
KR1020187025108A Active KR101991326B1 (ko) 2011-03-23 2012-03-23 오피오이드 수용체 리간드와 그 용도 및 제조방법

Country Status (22)

Country Link
US (8) US8835488B2 (enExample)
EP (3) EP3872076A1 (enExample)
JP (6) JP5912169B2 (enExample)
KR (3) KR102129247B1 (enExample)
CN (1) CN103702561B (enExample)
AU (2) AU2012230761B2 (enExample)
CA (1) CA2830742C (enExample)
CY (1) CY1119057T1 (enExample)
DK (2) DK3290415T3 (enExample)
EA (1) EA025456B1 (enExample)
ES (2) ES2857549T3 (enExample)
HR (1) HRP20171021T1 (enExample)
HU (2) HUE032948T2 (enExample)
IL (4) IL228506A (enExample)
LT (1) LT2688403T (enExample)
ME (1) ME02754B (enExample)
PL (2) PL3290415T3 (enExample)
PT (2) PT2688403T (enExample)
RS (1) RS56111B1 (enExample)
SI (1) SI2688403T1 (enExample)
SM (1) SMT201700325T1 (enExample)
WO (1) WO2012129495A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2688403T (pt) * 2011-03-23 2017-07-13 Trevena Inc Ligandos de recetores opioides e métodos de uso e fabrico dos mesmos
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
JP2018532772A (ja) 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
EP3350158A4 (en) 2015-09-16 2019-05-08 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP6824502B2 (ja) * 2015-10-15 2021-02-03 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． オキサスピロ誘導体、その製造方法、及び医薬におけるその適用
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
HK1251472A1 (zh) * 2015-12-14 2019-02-01 特维娜有限公司 治療痛覺過敏的方法
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
KR20180094938A (ko) * 2015-12-17 2018-08-24 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 시토크롬 p450 억제제의 결합
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
JP6889186B2 (ja) * 2016-07-01 2021-06-18 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 疼痛を治療するための重水素化合物
KR102180740B1 (ko) 2016-08-19 2020-11-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
WO2018108319A1 (en) * 2016-12-16 2018-06-21 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
WO2018152293A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016775A2 (pt) * 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
CA3056019A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3596053B1 (en) 2017-03-15 2023-08-16 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
TW201836606A (zh) * 2017-04-14 2018-10-16 大陸商江蘇恆瑞醫藥股份有限公司 一種ｍｏｒ激動劑與ｋｏｒ激動劑聯合在製備緩解和／或治療疼痛的藥物中的用途
TWI682929B (zh) * 2017-04-14 2020-01-21 大陸商江蘇恒瑞醫藥股份有限公司 一種阿片樣物質受體（mor）激動劑的鹽、其富馬酸鹽i晶型及製備方法
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN109206417B (zh) * 2017-07-04 2023-01-03 四川海思科制药有限公司 阿片受体激动剂及其应用
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US11072601B2 (en) 2017-09-18 2021-07-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
TWI690524B (zh) * 2017-09-28 2020-04-11 大陸商江蘇恒瑞醫藥股份有限公司 氧雜螺環類衍生物的製備方法及其中間產物
US11124523B2 (en) 2017-10-13 2021-09-21 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof
US11471503B2 (en) 2017-12-06 2022-10-18 Jiangsu Hengrui Medicine Co., Ltd. Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain
WO2019152946A1 (en) 2018-02-05 2019-08-08 Alkermes, Inc. Compounds for the treatment of pain
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
CA3175384A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
TW202015678A (zh) * 2018-05-14 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｍｏｒ受體激動劑醫藥組成物
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
DK3852748T3 (da) 2018-09-18 2025-10-06 Lilly Co Eli Farnesoid x-receptor-agonister og deres anvendelse
CN112638907B (zh) * 2018-10-12 2022-04-12 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020073984A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112334465B (zh) * 2019-01-17 2024-06-11 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
EP4643882A2 (en) 2019-11-26 2025-11-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
CN113412263B (zh) 2020-01-17 2024-07-26 上海海雁医药科技有限公司 氮杂双环取代的氧杂螺环衍生物、其制法与医药上的用途
CA3164581A1 (en) * 2020-01-17 2021-07-22 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Optically pure oxaspiro-substituted pyrrolopyrazole derivative, preparation method therefor and pharmaceutical use thereof
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2022033380A1 (zh) * 2020-08-10 2022-02-17 成都苑东生物制药股份有限公司 一种mor受体激动剂化合物、制备方法及其用途
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
WO2022143715A1 (zh) 2020-12-29 2022-07-07 上海海雁医药科技有限公司 氧杂螺环取代的吡咯并吡唑衍生物及其中间体和制备方法
EP4361154A4 (en) * 2021-07-13 2025-06-18 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt of a Mor receptor agonist, polymorph thereof, and use thereof
CN115677675B (zh) * 2021-07-21 2025-09-12 成都苑东生物制药股份有限公司 一种6-氧杂螺[4,5]癸烷类化合物的盐、制备方法及用途
IL310506A (en) * 2021-08-02 2024-03-01 Shujing Biopharma Co Ltd An oxaspiro derivative, a method for its preparation and use
WO2023030319A1 (zh) * 2021-08-31 2023-03-09 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
JP7736929B2 (ja) 2021-12-03 2025-09-09 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CN116041336B (zh) * 2022-01-21 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN118638109B (zh) * 2024-04-30 2025-10-28 中山大学 一种阿片类药物-奥赛利定的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
US5223530A (en) 1990-07-31 1993-06-29 Sri, International Arylcycloalkanepolyalkylamine ligands
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
AU3192295A (en) * 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
PL212616B1 (pl) * 2002-09-19 2012-10-31 Lilly Co Eli Eter diarylowy i kompozycja farmaceutyczna zawierajaca ten eter
US7338962B2 (en) * 2003-10-01 2008-03-04 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US20100022637A1 (en) * 2005-09-29 2010-01-28 The Trustees Of Columbia University In The City Of New York Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008057856A2 (en) * 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
JP2010508358A (ja) * 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
WO2009018169A1 (en) 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
US8293758B2 (en) * 2008-03-27 2012-10-23 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives
FR2939136B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
PT2688403T (pt) * 2011-03-23 2017-07-13 Trevena Inc Ligandos de recetores opioides e métodos de uso e fabrico dos mesmos
HK1251472A1 (zh) 2015-12-14 2019-02-01 特维娜有限公司 治療痛覺過敏的方法

Also Published As

Publication number Publication date
US20190343819A1 (en) 2019-11-14
IL228506A0 (en) 2013-12-31
IL284407B (en) 2022-12-01
CY1119057T1 (el) 2018-01-10
US9642842B2 (en) 2017-05-09
JP2023075282A (ja) 2023-05-30
IL228506A (en) 2016-11-30
AU2012230761A1 (en) 2013-05-02
AU2017200745B2 (en) 2018-02-22
IL243318A0 (en) 2016-02-29
JP2016155843A (ja) 2016-09-01
KR101991326B1 (ko) 2019-06-20
PL2688403T3 (pl) 2017-09-29
JP2020073570A (ja) 2020-05-14
JP6649341B2 (ja) 2020-02-19
AU2012230761B2 (en) 2016-11-03
BR112013024136A2 (pt) 2020-01-14
US20220175747A1 (en) 2022-06-09
JP2018048193A (ja) 2018-03-29
KR101991327B1 (ko) 2019-06-20
PT2688403T (pt) 2017-07-13
US20160250199A1 (en) 2016-09-01
CA2830742C (en) 2023-03-14
US20170326124A1 (en) 2017-11-16
JP5912169B2 (ja) 2016-04-27
JP2014508811A (ja) 2014-04-10
EP2688403A1 (en) 2014-01-29
US9849119B2 (en) 2017-12-26
JP6243949B2 (ja) 2017-12-06
CA2830742A1 (en) 2012-09-27
PL3290415T3 (pl) 2021-07-19
US20150246904A1 (en) 2015-09-03
WO2012129495A1 (en) 2012-09-27
HK1250984A1 (en) 2019-01-18
US9309234B2 (en) 2016-04-12
US20180311222A1 (en) 2018-11-01
ME02754B (me) 2018-01-20
EA025456B1 (ru) 2016-12-30
AU2017200745A1 (en) 2017-02-23
RS56111B1 (sr) 2017-10-31
IL284407B2 (en) 2023-04-01
JP2021176885A (ja) 2021-11-11
NZ615993A (en) 2015-11-27
US20120245181A1 (en) 2012-09-27
EP3290415A1 (en) 2018-03-07
CN103702561A (zh) 2014-04-02
US20130331408A1 (en) 2013-12-12
SMT201700325T1 (it) 2017-09-07
IL284407A (en) 2021-08-31
ES2857549T3 (es) 2021-09-29
IL243318B (en) 2020-02-27
PT3290415T (pt) 2021-03-29
KR20140047599A (ko) 2014-04-22
EP2688403A4 (en) 2014-10-15
CN103702561B (zh) 2017-02-22
KR20190072665A (ko) 2019-06-25
JP7248750B2 (ja) 2023-03-29
ES2632009T3 (es) 2017-09-07
US8835488B2 (en) 2014-09-16
EP3872076A1 (en) 2021-09-01
KR20180100453A (ko) 2018-09-10
US11077098B2 (en) 2021-08-03
US10588898B2 (en) 2020-03-17
US11931350B2 (en) 2024-03-19
IL272165B (en) 2021-07-29
NZ713143A (en) 2017-05-26
EP2688403B1 (en) 2017-05-31
DK3290415T3 (da) 2021-03-22
DK2688403T3 (en) 2017-07-24
JP6923683B2 (ja) 2021-08-25
EA201391332A1 (ru) 2014-04-30
HUE032948T2 (en) 2017-11-28
HUE054055T2 (hu) 2021-08-30
IL272165A (en) 2020-03-31
EP3290415B1 (en) 2020-12-30
US9044469B2 (en) 2015-06-02
SI2688403T1 (sl) 2017-08-31
HRP20171021T1 (hr) 2017-09-22
LT2688403T (lt) 2017-07-25

Similar Documents

Publication Publication Date Title
KR102129247B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
CN108601775A (zh) 阿片受体配体和细胞色素p450抑制剂的组合
HK1196035B (en) Opioid receptor ligands and methods of using and making same
HK1196035A (en) Opioid receptor ligands and methods of using and making same
HK1254306A1 (en) Combinations of opioid receptor ligands and cytochrome p450 inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6